Impact of IFM 2009 and DETERMINATION Studies

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

Triplet therapy with VRd has improved progression-free survival in NDMM, altering induction treatment strategies.
Clinicians now prioritize aggressive initial treatment to maximize PFS, influenced by VRd's efficacy.
The DETERMINATION trial highlighted the benefits of VRd with upfront transplantation, reinforcing longer PFS as a primary goal.
Subsequent studies focus on optimizing induction regimens and treatment sequencing based on these findings.

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

Now Viewing

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

Video content above is prompted by the following:

The pivotal IFM 2009 study found that VRd (bortezomib, lenalidomide, and dexamethasone) followed by transplantation significantly improved progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM). How did the introduction of triplet therapy prior to transplant change the clinician mindset when deciding induction treatment, and how has that impacted studies that came after?
(Dr Adams) In DETERMINATION, VRd with upfront transplant was associated with longer PFS. How did this trial change the goals of primary therapy for patients with NDMM?